Related Experiment Video
Updated: May 29, 2026
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts
Hetal Pandya1, Denise M Gibo, Shivank Garg
1Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA. debinski@wfubmc.edu
Abstract:
Interleukin 13 receptor α 2 (IL-13Rα2) is a glioblastoma multiforme (GBM)-associated plasma membrane receptor, a brain tumor of dismal prognosis. Here, we isolated peptide ligands for IL-13Rα2 with use of a cyclic disulphide-constrained heptapeptide phages display library and 2 in vitro biopanning schemes with GBM cells that do (G26-H2 and SnB19-pcDNA cells) or do not (G26-V2 and SnB19-asIL-13Rα2 cells) over-express IL-13Rα2. We identified 3 peptide phages that bind to IL-13Rα2 in cellular and protein assays. One of the 3 peptide phages, termed Pep-1, bound to IL-13Rα2 with the highest specificity, surprisingly, also in a reducing environment. Pep-1 was thus synthesized and further analyzed in both linear and disulphide-constrained forms. The linear peptide bound to IL-13Rα2 more avidly than did the disulphide-constrained form and was efficiently internalized by IL-13Rα2-expressing GBM cells. The native ligand, IL-13, did not compete for the Pep-1 binding to the receptor and vice versa in any of the assays, indicating that the peptide might be binding to a site on the receptor different from the native ligand. Furthermore, we demonstrated by noninvasive near infrared fluorescence imaging in nude mice that Pep-1 binds and homes to both subcutaneous and orthotopic human GBM xenografts expressing IL-13Rα2 when injected by an intravenous route. Thus, we identified a linear heptapeptide specific for the IL-13Rα2 that is capable of crossing the blood-brain tumor barrier and homing to tumors. Pep-1 can be further developed for various applications in cancer and/or inflammatory diseases.
Insights
Researchers identified Pep-1, a novel peptide that specifically targets Interleukin 13 receptor α 2 (IL-13Rα2) on glioblastoma cells. This peptide shows potential for targeted cancer therapy by crossing the blood-brain tumor barrier.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with a poor prognosis.
- Interleukin 13 receptor α 2 (IL-13Rα2) is a cell surface receptor frequently overexpressed in GBM.
- Targeting IL-13Rα2 presents a promising strategy for developing novel GBM therapies.
Purpose of the Study:
- To isolate and characterize novel peptide ligands that specifically bind to IL-13Rα2.
- To evaluate the potential of these peptides for targeted delivery to GBM tumors.
- To explore new therapeutic avenues for glioblastoma treatment.
Main Methods:
- Utilized a heptapeptide phage display library and biopanning techniques with IL-13Rα2-expressing and non-expressing GBM cells.
- Performed cellular and protein binding assays to identify specific IL-13Rα2 binders.
- Synthesized and tested linear and constrained forms of the lead peptide (Pep-1) in vitro and in vivo using near-infrared fluorescence imaging.
Main Results:
- Identified three peptide phages that bind to IL-13Rα2, with Pep-1 showing the highest specificity.
- Linear Pep-1 demonstrated avid binding and efficient internalization by IL-13Rα2-expressing GBM cells, distinct from IL-13 binding.
- In vivo imaging confirmed that intravenously administered Pep-1 homes to both subcutaneous and orthotopic human GBM xenografts expressing IL-13Rα2.
Conclusions:
- A novel linear heptapeptide, Pep-1, has been identified with high specificity for IL-13Rα2.
- Pep-1 can effectively cross the blood-brain tumor barrier and target GBM xenografts.
- Pep-1 holds significant potential for the development of targeted therapies for glioblastoma and other IL-13Rα2-associated diseases.
